Standard treatment compared to intensified treatment with pegfilgrastim support in patients with small-cell lung cancer, limited disease. A phase III study. - The STING 2 study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-005754-80-SE

Enrollment

Unknown

Registered

2007-08-24

Start date

2007-10-15

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer (limited disease)

Interventions

Trade Name: Neulasta Holoxan Etopofos Carboplatin Product Name: Holoxan/Neulasta/Etopos/Paraplatin Pharmaceutical Form: Injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically verified diagnosis of small cell lung cancer Limited disease as stage I,II or III Performance status 3 * 10(9)/L Thrombocyte count (TPC) > 100*10(9)/L ASAT/ALAT =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Serious heart disease, kidney disease, impaired lung function or other disease which may pose risk to standard treatment Reduced ability to cooperate Performance status 3 and 4 History of malignant disease other than basal cell carcinoma or stage I cancer of the cervix Pregnant or breast feeding

Design outcomes

Primary

Measure	Time frame
Main Objective: 2 year survival;Secondary Objective: 5 year survival and overall survival as well as toxicity, frequency of CR and good PR;Primary end point(s): 2 year survival	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026